Healthcare company Baxter International (NYSE: BAX) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.3% year on year to $2.96 billion. Its non-GAAP profit of $0.56 per share was 52.5% above analysts’ consensus estimates.

Is now the time to buy Baxter? Find out by accessing our full research report, it’s free.

Company Overview

With a history dating back to 1931 and products used in over 100 countries, Baxter International (NYSE: BAX) provides essential healthcare products including dialysis therapies, IV solutions, infusion systems, surgical products, and patient monitoring technologies to hospitals and clinics worldwide.

Revenue Growth

Examining a company’s long-term performance can provide clues about its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last five years, Baxter’s demand was weak and its revenue declined by 1.2% per year. This was below our standards and is a sign of poor business quality.

Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. Baxter’s annualized revenue growth of 4.5% over the last two years is above its five-year trend, which is encouraging.

We can better understand the company’s sales dynamics by analyzing its constant currency revenue, which excludes currency movements that are outside their control and not indicative of demand. Over the last two years, its constant currency sales averaged 2.6% year-on-year growth. Because this number is lower than its normal revenue growth, we can see that foreign exchange rates have boosted Baxter’s performance.

This quarter, Baxter reported year-on-year revenue growth of 5.3%, and its $2.96 billion of revenue exceeded Wall Street’s estimates by 6%.

Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months, a deceleration versus the last two years. This projection is underwhelming and implies its products and services will see some demand headwinds.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Adjusted Operating Margin

Baxter has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average adjusted operating margin of 15.1%.

Looking at the trend in its profitability, Baxter’s adjusted operating margin decreased by 4.8 percentage points over the last five years. The company’s two-year trajectory also shows it failed to get its profitability back to the peak as its margin fell by 1.6 percentage points. This performance was poor no matter how you look at it - it shows its expenses were rising and it couldn’t pass those costs onto its customers.

This quarter, Baxter generated an adjusted operating margin profit margin of 14.2%, in line with the same quarter last year. This indicates the company’s overall cost structure has been relatively stable.

Earnings Per Share

Revenue trends explain a company’s historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth — for example, a company could inflate its sales through excessive spending on advertising and promotions.

Sadly for Baxter, its EPS declined by 8.5% annually over the last five years, more than its revenue. This tells us the company struggled because its fixed cost base made it difficult to adjust to shrinking demand.

We can take a deeper look into Baxter’s earnings to better understand the drivers of its performance. As we mentioned earlier, Baxter’s adjusted operating margin was flat this quarter but declined by 4.8 percentage points over the last five years. Its share count also grew by 1.8%, meaning the company not only became less efficient with its operating expenses but also diluted its shareholders.

In Q2, Baxter reported adjusted EPS of $0.56, down from $0.59 in the same quarter last year. Despite falling year on year, this print easily cleared analysts’ estimates. Over the next 12 months, Wall Street expects Baxter’s full-year EPS to stay about the same, moving from $2.05 to $2.06.

Key Takeaways from Baxter’s Q2 Results

It was good to see Baxter beat analysts’ EPS expectations this quarter. We were also excited its revenue outperformed Wall Street’s estimates by a wide margin. Zooming out, we think this was a good print with some key areas of upside. The stock traded up 16.1% to $28.74 immediately after reporting.

Indeed, Baxter had a rock-solid quarterly earnings result, but is this stock a good investment here? What happened in the latest quarter matters, but not as much as longer-term business quality and valuation, when deciding whether to invest in this stock. We cover that in our actionable full research report which you can read here (it’s free).